• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

不祥组合：新冠肺炎与真菌血症——病例报告及文献综述

Ominous combination: COVID-19 disease and fungemia-Case report and review of the literature.

作者信息

Goravey Wael, Ali Gawahir A, Ali Masia, Ibrahim Emad B, Al Maslamani Muna, Abdel Hadi Hamad

机构信息

Department of Infectious Diseases Communicable Diseases Centre Hamad Medical Corporation Doha Qatar.

Department of Laboratory Medicine and Pathology Hamad Medical Corporation Doha Qatar.

出版信息

Clin Case Rep. 2021 Sep 12;9(9):e04827. doi: 10.1002/ccr3.4827. eCollection 2021 Sep.

DOI:10.1002/ccr3.4827
PMID:34532055
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8435228/
Abstract

The identification of fungemia in critically ill COVID-19 patients is detrimental, with huge implications on patient mortality and infectious control measures.

摘要

在危重症COVID-19患者中识别真菌血症是有害的，对患者死亡率和感染控制措施有重大影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6319/8435228/4bb0ef2fa674/CCR3-9-e04827-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6319/8435228/c1c9924fd643/CCR3-9-e04827-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6319/8435228/4bb0ef2fa674/CCR3-9-e04827-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6319/8435228/c1c9924fd643/CCR3-9-e04827-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6319/8435228/4bb0ef2fa674/CCR3-9-e04827-g001.jpg

相似文献

1
Ominous combination: COVID-19 disease and fungemia-Case report and review of the literature.不祥组合：新冠肺炎与真菌血症——病例报告及文献综述
Clin Case Rep. 2021 Sep 12;9(9):e04827. doi: 10.1002/ccr3.4827. eCollection 2021 Sep.
2
[First Case of COVID-19 Positive Candida auris Fungemia in Turkey].[土耳其首例新冠病毒检测呈阳性的耳念珠菌血症病例]
Mikrobiyol Bul. 2021 Oct;55(4):648-655. doi: 10.5578/mb.20219716.
3
Cutaneous manifestations of a 21st century worldwide fungal epidemic possibly complicating the COVID-19 pandemic to jointly menace mankind.二十一世纪全球真菌性传染病的皮肤表现，可能使人类共同面临的 COVID-19 大流行更加复杂。
Dermatol Ther. 2020 Jul;33(4):e13481. doi: 10.1111/dth.13481. Epub 2020 May 27.
4
Candida auris Blood stream infection- a descriptive study from Qatar.Candida auris 血流感染-来自卡塔尔的描述性研究。
BMC Infect Dis. 2023 Aug 6;23(1):513. doi: 10.1186/s12879-023-08477-5.
5
C. auris and non-C. auris candidemia in hospitalized adult and pediatric COVID-19 patients; single center data from Pakistan.住院成人及儿童新冠病毒病患者中的耳念珠菌及非耳念珠菌血症；来自巴基斯坦的单中心数据
Med Mycol. 2021 Dec 3;59(12):1238-1242. doi: 10.1093/mmy/myab057.
6
Multidrug-Resistant Fungemia in Critical Care Units: Experience from a Tertiary Care Hospital in India.重症监护病房中的多重耐药真菌血症：来自印度一家三级护理医院的经验。
Microb Drug Resist. 2020 Feb;26(2):145-149. doi: 10.1089/mdr.2019.0021. Epub 2019 Sep 20.
7
Prevalence, risk factors, treatment and outcome of multidrug resistance Candida auris infections in Coronavirus disease (COVID-19) patients: A systematic review.新型冠状病毒肺炎（COVID-19）患者中耐多药耳念珠菌感染的流行情况、危险因素、治疗方法和结局：系统评价。
Mycoses. 2022 Jun;65(6):613-624. doi: 10.1111/myc.13447.
8
Analysis of Candida auris fungemia at a single facility in Kenya.肯尼亚某单一医疗机构的耳念珠菌菌血症分析。
Int J Infect Dis. 2019 Aug;85:182-187. doi: 10.1016/j.ijid.2019.06.001. Epub 2019 Jun 8.
9
Nosocomial fungemia by Candida auris: First four reported cases in continental Europe.耳念珠菌引起的医院获得性真菌血症：欧洲大陆报告的首例4例病例
Rev Iberoam Micol. 2017 Jan-Mar;34(1):23-27. doi: 10.1016/j.riam.2016.11.002. Epub 2017 Jan 25.
10
Candida auris from colonisation to candidemia: A four-year study.从定植到念珠菌血症的耳念珠菌：一项为期四年的研究。
Mycoses. 2023 Oct;66(10):882-890. doi: 10.1111/myc.13626. Epub 2023 Jul 4.

引用本文的文献

1
Epidemiology of Candidemia, Candiduria and Emerging Candidozyma (Candida) auris Across Gulf Cooperative Council Countries and Yemen in the Arabian Peninsula.阿拉伯半岛海湾合作委员会国家和也门念珠菌血症、念珠菌尿症及新兴耳念珠菌（假丝酵母菌属）的流行病学
Mycoses. 2025 Jun;68(6):e70073. doi: 10.1111/myc.70073.
2
Diagnostic Challenges in Fungal Coinfections Associated With Global COVID-19.与全球新冠疫情相关的真菌合并感染的诊断挑战
Scientifica (Cairo). 2025 May 7;2025:6840605. doi: 10.1155/sci5/6840605. eCollection 2025.
3
The laboratory investigation, management, and infection prevention and control of : a narrative review to inform the 2024 national guidance update in England.

本文引用的文献

1
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.托珠单抗治疗 COVID-19 住院患者的疗效（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.
2
First Outbreak during a COVID-19 Pandemic in a Tertiary-Care Center in Lebanon.黎巴嫩一家三级医疗中心在新冠疫情期间的首次疫情爆发。
Pathogens. 2021 Feb 3;10(2):157. doi: 10.3390/pathogens10020157.
3
Outbreak of Candida auris infection in a COVID-19 hospital in Mexico.
实验室调查、管理以及感染预防和控制：一篇叙述性综述，旨在为 2024 年英格兰国家指南更新提供信息。
J Med Microbiol. 2024 May;73(5). doi: 10.1099/jmm.0.001820.
4
in Intensive Care Setting: The First Case Reported in Portugal.在重症监护环境中：葡萄牙首例报告病例。
J Fungi (Basel). 2023 Aug 9;9(8):837. doi: 10.3390/jof9080837.
5
and COVID-19: A health threatening combination.以及新型冠状病毒肺炎：一种威胁健康的组合。
Curr Med Mycol. 2022 Sep;8(3):44-50. doi: 10.18502/cmm.8.3.11211.
6
Prevalence, risk factors, treatment and outcome of multidrug resistance Candida auris infections in Coronavirus disease (COVID-19) patients: A systematic review.新型冠状病毒肺炎（COVID-19）患者中耐多药耳念珠菌感染的流行情况、危险因素、治疗方法和结局：系统评价。
Mycoses. 2022 Jun;65(6):613-624. doi: 10.1111/myc.13447.
墨西哥一家新冠肺炎医院爆发耳念珠菌感染
Clin Microbiol Infect. 2021 Jan 8;27(5):813-6. doi: 10.1016/j.cmi.2020.12.030.
4
Spread of Carbapenem-Resistant Gram-Negatives and during the COVID-19 Pandemic in Critically Ill Patients: One Step Back in Antimicrobial Stewardship?耐碳青霉烯类革兰阴性菌在新冠肺炎大流行期间在重症患者中的传播：抗菌药物管理后退一步？
Microorganisms. 2021 Jan 3;9(1):95. doi: 10.3390/microorganisms9010095.
5
Candida auris: A Latent Threat to Critically Ill Patients With Coronavirus Disease 2019.耳念珠菌：对2019冠状病毒病重症患者的潜在威胁。
Clin Infect Dis. 2021 Nov 2;73(9):e2836-e2837. doi: 10.1093/cid/ciaa1595.
6
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.COVID-19 重症患者全身使用皮质类固醇与死亡率的关联：一项荟萃分析。
JAMA. 2020 Oct 6;324(13):1330-1341. doi: 10.1001/jama.2020.17023.
7
Multidrug-Resistant Candida auris Infections in Critically Ill Coronavirus Disease Patients, India, April-July 2020.2020 年 4 月至 7 月，印度新冠肺炎重症患者中出现耐多药念珠菌血症感染。
Emerg Infect Dis. 2020 Nov;26(11):2694-2696. doi: 10.3201/eid2611.203504. Epub 2020 Aug 27.
8
Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19.托珠单抗治疗 COVID-19 机械通气患者。
Clin Infect Dis. 2021 Jul 15;73(2):e445-e454. doi: 10.1093/cid/ciaa954.
9
The lurking scourge of multidrug resistant Candida auris in times of COVID-19 pandemic.新冠疫情期间多重耐药耳念珠菌这一潜在祸害。
J Glob Antimicrob Resist. 2020 Sep;22:175-176. doi: 10.1016/j.jgar.2020.06.003. Epub 2020 Jun 12.
10
Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?托珠单抗治疗新型冠状病毒肺炎细胞因子风暴综合征：念珠菌血症风险增加？
Autoimmun Rev. 2020 Jul;19(7):102564. doi: 10.1016/j.autrev.2020.102564. Epub 2020 May 5.